title: [A study on immunogenicity and safety of bivalent inactivated vaccine against hemorrhagic fever with renal syndrome].
abstract: OBJECTIVE
  To study side effects and effectiveness of bivalent inactivated vaccine against hemorrhagic fever with renal syndrome in population of a randomized controlled field trial.
  
  
  METHODS
  Serum indirect immunofluorescent antibody in 167 persons and neutralization antibody (types I and II) in 69 persons, who received three-dose vaccine, were determined two weeks after immunization, and side effects in 657 vaccinees were observed within 72 houses after immunization.
  
  
  RESULTS
  Serum positive conversion rate of indirect immunofluorescent antibody was 99.04% (166/167) with GMT of 24.51 +/- 2.06. Serum positive conversion rate of neutralization antibody was 100% (69/69), 91.30% (63/69) for types I and 88.41% (61/69) for type II, respectively. GMTs for type I and II neutralization antibody were 18.27 +/- 2.21 and 12.47 +/- 2.16, respectively. Side effects at local site vaccinated of the body and temperature rising could be seen in 1.48% and 0.36% of the vaccinees, respectively. No severe side effect and abnormal reaction was found in vaccinees on the field.
  
  
  CONCLUSIONS
  Immune response to bivalent inactivated vaccine against hemorrhagic fever with renal syndrome was satisfactory with slight side effect.
authors.affiliation: Department of Epidemiology, Shanghai Medical University, Shanghai 200032.
authors.forename: Y
authors.initials: Y
authors.lastname: Ruan
authors.forename: X
authors.initials: X
authors.lastname: Xu
authors.forename: W
authors.initials: W
authors.lastname: Liu
authors.forename: X
authors.initials: X
authors.lastname: Deng
authors.forename: S
authors.initials: S
authors.lastname: Weng
authors.forename: W
authors.initials: W
authors.lastname: Zhou
authors.forename: Q
authors.initials: Q
authors.lastname: Wang
authors.forename: L
authors.initials: L
authors.lastname: Chen
authors.forename: L
authors.initials: L
authors.lastname: Fang
authors.forename: Z
authors.initials: Z
authors.lastname: Xu
authors.forename: Q
authors.initials: Q
authors.lastname: Yan
authors.forename: W
authors.initials: W
authors.lastname: Liu
authors.forename: G
authors.initials: G
authors.lastname: Dong
authors.forename: H
authors.initials: H
authors.lastname: Gu
authors.forename: Y
authors.initials: Y
authors.lastname: Yu
authors.forename: Z
authors.initials: Z
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D018063:Hantaan virus / Q000276:immunology*; D006480:Hemorrhagic Fever with Renal Syndrome / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014765:Viral Vaccines